Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab

Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab

The identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of metastatic-colorectal-cancer (mCRC) patients. We previously reported the relevance of VEGF-A and some components of the renin–angiotensin-aldosterone system (R...

Full description

Bibliographic Details
Main Authors: M. José Ortiz-Morales, Marta Toledano-Fonseca, Rafael Mena-Osuna, M. Teresa Cano, Auxiliadora Gómez-España, Juan R. De la Haba-Rodríguez, Antonio Rodríguez-Ariza, Enrique Aranda
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
VEGF-A
angiotensin-converting enzyme
colorectal cancer
anti-angiogenic drug
bevacizumab
prognosis
Online Access:https://www.mdpi.com/2072-6694/14/13/3054

Internet

https://www.mdpi.com/2072-6694/14/13/3054

Similar Items